DK2822966T3 - Treatment of mucositis with immunoglobulin a - Google Patents

Treatment of mucositis with immunoglobulin a Download PDF

Info

Publication number
DK2822966T3
DK2822966T3 DK13708170.9T DK13708170T DK2822966T3 DK 2822966 T3 DK2822966 T3 DK 2822966T3 DK 13708170 T DK13708170 T DK 13708170T DK 2822966 T3 DK2822966 T3 DK 2822966T3
Authority
DK
Denmark
Prior art keywords
composition
use according
iga
mucositis
immunoglobulin
Prior art date
Application number
DK13708170.9T
Other languages
Danish (da)
English (en)
Inventor
Christoph Aebi
Alexander Schaub
Sylvia Miescher
Sonja Christina Lueer
Cedric Pierre Vonarburg
Adrian Zuercher
Original Assignee
Univ Bern
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bern, Csl Behring Ag filed Critical Univ Bern
Application granted granted Critical
Publication of DK2822966T3 publication Critical patent/DK2822966T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK13708170.9T 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin a DK2822966T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12158939.4A EP2636683A1 (en) 2012-03-09 2012-03-09 Treatment of mucositis with Immunoglobulin
PCT/EP2013/054722 WO2013132063A1 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Publications (1)

Publication Number Publication Date
DK2822966T3 true DK2822966T3 (en) 2018-02-26

Family

ID=45808320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13708170.9T DK2822966T3 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin a

Country Status (10)

Country Link
US (1) US9546209B2 (enExample)
EP (2) EP2636683A1 (enExample)
JP (1) JP6238910B2 (enExample)
KR (1) KR102120620B1 (enExample)
CN (1) CN104254543B (enExample)
AU (1) AU2013201394B2 (enExample)
CA (1) CA2865810C (enExample)
DK (1) DK2822966T3 (enExample)
ES (1) ES2660157T3 (enExample)
WO (1) WO2013132063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
CN104254542A (zh) 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
AU2017357044B2 (en) 2016-11-10 2024-01-04 Becton, Dickinson And Company Timeline system for monitoring a culture media protocol
JP2026502571A (ja) * 2023-01-13 2026-01-23 マイケル アール． サイモン 壊死性腸炎を治療するための分泌型ＩｇＡおよび分泌型ＩｇＭの調製方法およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
US9546209B2 (en) 2017-01-17
CA2865810A1 (en) 2013-09-12
EP2822966B1 (en) 2017-11-29
KR102120620B1 (ko) 2020-06-10
CA2865810C (en) 2022-09-06
CN104254543B (zh) 2018-06-05
JP6238910B2 (ja) 2017-11-29
AU2013201394B2 (en) 2015-09-03
JP2015513554A (ja) 2015-05-14
CN104254543A (zh) 2014-12-31
KR20140145587A (ko) 2014-12-23
US20150030613A1 (en) 2015-01-29
EP2636683A1 (en) 2013-09-11
EP2822966A1 (en) 2015-01-14
WO2013132063A1 (en) 2013-09-12
ES2660157T3 (es) 2018-03-21
AU2013201394A1 (en) 2013-09-26
HK1204629A1 (en) 2015-11-27

Similar Documents

Publication Publication Date Title
TWI891945B (zh) 抗tslp抗體藥物組合物及其用途
EP3819313A1 (en) Bispecific antibody and use thereof
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
JP2019038834A (ja) 分泌様免疫グロブリンを含む組成物
EP2822966B1 (en) Treatment of mucositis with immunoglobulin a
KR102962504B1 (ko) Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
US20070036734A1 (en) Therapeutic agent for periodontal disease
TW202144420A (zh) 一種免疫細胞啟動劑的開發及應用
JP2025165988A (ja) プラスミノーゲンとの結合のための抗体
HK1204629B (en) Treatment of mucositis with immunoglobulin a
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
KR102241619B1 (ko) 병원체의 면역 억제 기능을 저해하는 모노클로날 항체, 그의 항원 결합 단편 및 이러한 항체를 생성하는 하이브리도마
US20170342136A1 (en) Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases
TWI665215B (zh) 具有抑制致病原的免疫抑制功能的單株抗體，其抗原結合片段，以及產生該等抗體的融合瘤
TW202434625A (zh) Lag-3及pd-1/lag-3抗體